Community acquired pneumonia
This presentation is the property of its rightful owner.
Sponsored Links
1 / 47

Community Acquired Pneumonia PowerPoint PPT Presentation


  • 162 Views
  • Uploaded on
  • Presentation posted in: General

Community Acquired Pneumonia. Dr. Leena Mane PGY3 Resident Emory Family Medicine. Objectives. Name the common infectious causes of pneumonia in US Discuss the evidence based workup for pneumonia List the criteria for deciding on outpatient vs inpatient vs ICU Rx of pneumonia

Download Presentation

Community Acquired Pneumonia

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Community acquired pneumonia

Community Acquired Pneumonia

Dr. Leena Mane

PGY3 Resident

Emory Family Medicine


Objectives

Objectives

  • Name the common infectious causes of pneumonia in US

  • Discuss the evidence based workup for pneumonia

  • List the criteria for deciding on outpatient vs inpatient vs ICU Rx of pneumonia

  • Name the evidence based antibiotics for treatment


Outline

Outline

  • Epidemiology and etiology

  • Diagnosis

  • Admission decision

  • The workup for C.A.P.

  • Treatment- what to use, how to use,how long

  • Recovery


Epidemiology

Epidemiology

  • 7 th most common cause of death in U.S.

  • 5.6 million cases annually

  • Annual Health care cost 8.4 billion

  • Definition- pneumonia not acquired in a hospital or long term care facility


Etiology of c a p

Etiology of C.A.P

  • No etiology in ~ 50 %

  • > 2 etiologies in 2-5%

  • S. Pneumonia in : 2/3 of bacterial cases

    or 20 % of all cases

  • H. Influenzae ( non typeable)

  • Mycoplasma pneumonia

  • Chlamydia p ~12%

  • Influenza

  • Legionella ~ 5%


Atypical pneumonia

Atypical Pneumonia

  • Age (years)- less than 40

  • Onset- Gradual, coryzal prodrome

  • Cough- Paroxysmal, hacking non productive

  • Sputum- Minimal, mucoid

  • Rigors- Absent

  • Fever- Usually less than 39.5 °C


Atypical pneumonia ctd

Atypical Pneumonia ctd

  • Consolidation- Usually absent

  • Leucocytosis - usually absent

  • Chest x-ray- Initially interstitial, may progress to air space involvement


Atypical pneumonia1

Atypical pneumonia


Acute bacterial pneumonia

Acute Bacterial Pneumonia

  • Age ( in yrs) : less than 5, over 40

  • Onset : Abrupt

  • Cough : Productive

  • Sputum : Rusty & Purulent

  • Rigors : Frequently present

  • Fevers : > 39.5° c

  • Consolidation: present

  • Leucocytosis : 15- 25,000 with neutrophilia

  • Chest X-ray : alveolar with air bronchograms.


Community acquired pneumonia

When To Suspect Which Bug…..


Causes sign symptoms

Causes & sign & symptoms

  • S pneumonia – episodes of rigor, pleurisy,

    elderly , alcoholic

  • H. Influenzae -- COPD

  • M. catarhalis – COPD

  • Anaerobic -- Putrid Sputum

  • Influenza -- Winter epidemic

  • Chlamydia P -- S.T, HA, hoarseness


Causes sign symptoms1

Causes , Sign & symptoms

  • PCP -- Immunocompromised patients

  • Legionella – Severe illness, compromised host, Neg G.S.,organ transplant, outbreaks related with water source.

  • Mycoplasma P – 2-4 wks of prodrome, dry cough


Diagnosis

Cough/dyspnea /fever = CXR

EBM – II ( moderate)

Diagnosis


Admit or not

Admit or not

2 step decision rules


Step 1

Step 1

  • Assign to risk class I

    OR

  • Risk classes II- IV


Risk class i

Risk Class I

  • < 50 years of age

  • have none of five co- morbid conditions that increase mortality

  • Neoplasm

  • CHF

  • Renal disease

  • Cerebrovascular disease

  • Liver disease


Step approach

Step approach

  • If not in class I

    Go on to Step 2

    ( assign to one of classes II- V )


Step 2

Step 2

  • Assess patient’s severity index and assign a score

  • Demographics

  • Co- morbidities

  • P. E. findings

  • Lab findings


Demographics

Demographics

Characteristics Points

Age

Male age( in years)

Female age ( in years)- 10

Nursing home age ( in years) + 10

Residents


Co morbidities

Co- morbidities

Diseases Points

Neoplasm + 30

Liver disease + 20

CHF + 10

CVD + 10

Renal disease + 10


Physical exam

Physical exam

Finding Points

AMS + 20

RR> 30 + 20

SBP<90mm + 20

T<35 or > 40 + 15

P> 125 + 10


Laboratory

Laboratory

Findings Points

Ph<7.35 + 30

Na< 130 + 20

Hct < 30% + 10

PO2< 60 + 10

Pleural effusion + 10


The whole shootin match

The" whole ‘ Shootin’ Match "

Patient Assigned points

Demographics

Co- morbidities

P. E. finding

Lab finding


Stratification of risk score

Stratification of Risk Score

Risk Initial Treatment Risk class Based on

Low Outpatient I Algorithm

Outpatient II < 70 points

Medium Observation III 71-90 points

Inpatient IV 91- 130 point

High Inpatient (ICU) V > 130


Other considerations

Other considerations

  • Psychosocial contraindication to outpatient Rx

  • Compliance problems

  • Substance abuse

  • Cognitive impairment

  • Poor social support


Risk class mortality

Risk class mortality

Risk class Mortality

I 0. 1 % - outpatient

II 0. 6 % - outpatient

III 2.8 % - inpatient

IV 8.2 % - inpatient

V 29.2 % - inpatient


P s i

P. S. I.

  • Pneumonia severity index can serve as general guideline for management , clinical judgment should always supersede the prognostic scores.


Sensitivity specificity of diagnostics tests

Sensitivity & Specificity of diagnostics tests

Diagnostics Tests Sensitivity Specificity

Chlamydia

Rapid PCR( sputum) 30-90 >95

Serology( rise in Ab) 10 – 100 -

Sputum Cx 10- 80 >95

Gm Neg rods

Sputum GM stain 15- 100 11- 100


Sensitivity specificity ctd

Sensitivity & specificity ctd

Tests Sensitivity Specificity

H. Inf, Moraxella

Sputum Cx 20- 79 20- 79

Influenza

Rapid DFA 22-75 90

Legionella

DFA 22- 75 90

PCR 83- 100 >95

Serum acute titer 10- 27 >85

Urinary Ag 55- 90 > 95


Sensitivity specificity ctd1

Sensitivity & Specificity Ctd

Tests Sensitivity Specificity

Mycoplasma

Antibody Titers 75-95 >90

Cold Agglutinins 50- 60 -

PCR 30- 95 >95

Pneumococcal Pneumoniae

Chest X-ray 40 -

Sputum Cx 20- 79 20- 79

Sputum Gm stain 15- 100 11- 100


Blood culture

Blood Culture

  • Positive blood cultures had no correlations with severity of disease and outcome

  • Current ATS guidelines recommend that patient hospitalized for suspected CAP receive two sets of blood cultures.

  • However are not necessary for outpatient diagnosis


Inpatient work up

Inpatient work up

Inpatient

Sputum Cx Level II ( moderate)

Bld Cx Level I ( High)

BMP Level II

LFTs Level II

PO2 Level II


Sputum

Sputum

  • Level II evidence

  • Low power exam

  • Acceptable specimen

  • < 10 epithelial cells

  • > 25 PMNs


Sputum samples

Normal sputum

Moraxella catarrahalis

Sputum samples


Sputum samples1

H. Influezae

Klebsiella pneumoniae

Sputum Samples


Community acquired pneumonia

Pseudomonas

Strep Pneumoniae


Treatment

Target etiology

Watch for resistance pattern

Be aware of co- morbidities

Treatment


What to use

What to use

  • Outpatient

  • Macrolides

  • Fluroquinolones

  • Doxycycline


Management of cap

Management of CAP

Management of CAP


What to use1

What to use

  • Inpatient-

  • Fluroquinolones alone

  • Extended spectrum cephalosporins + macrolides

    Level II evidence


What to use2

What to Use

  • ICU patients

  • One of Cefotaxime, Ceftraixone, amp- sulbactum or pipercillin – tazobactum

    Plus

  • One of macrolides or fluroquinolones


Bug treatment

Bug & Treatment

Pathogen Abx

S. Pneumoniae Pen G, amoxicillin

fluroquinolones

H Influenzae bactrim, cefotaxime,

rocephin/carbapenam

S. Aureus nafcillin /vancomycin


Bug treatment1

Bug & Treatment

Pathogen Abx

Klebsiella carbapenams or 3rd

gen cephalosporins

Pseudomonas aminoglycoside plus

antipse. Penicillins or

Ceftazidime

Chlamydia Doxy or quinolones

Legionella Azithromycin or quinolones

Anaerobes Clindamycin


Recovery

Recovery

Symtoms Time period

Subjective Response 1-3 days

Fever without bacteremia - 2.5 days

with bacteremia – 6-7 days


Recovery1

Recovery

Symptoms Time period

CXR non elderly 30 days

older patients 6-8 wks

Legionella 12 wks

Fatigue non elderly 30- 45 days

elderly 90 days


Prevention

Pneumococcal vaccine

Influenza vaccine

Prevention


Bibliography

Bibliography

  • Diagnosis & treatment of CAP- aafp 2006

  • IDSA/ATS consensus guidelines on management of community acquired pneumonia in adults


  • Login